European Academy of Dermatology and Venereology Congress

European Academy of Dermatology and Venereology Congress

Source:

Strober B, et al. Tapinarof cream 1% once daily for plaque psoriasis: A long-term extension trial of a novel therapeutic aryl hydrocarbon receptor modulating agent. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 29-Oct. 2, 2021 (virtual meeting).

Disclosures: Stein Gold reports consulting for Arcutis, Amgen, Bristol Myers Squibb, Dermavant Sciences Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic and UCB Pharma; receiving grants from Arcutis, Amgen, Dermavant Sciences Inc., Eli Lilly, LEO Pharma and Ortho Dermatologic; and receiving payment for the development of educational presentations from Amgen, LEO Pharma and Ortho Dermatologic.
October 06, 2021
1 min read
Save

Long-term tapinarof efficacious in plaque psoriasis clearance

Source:

Strober B, et al. Tapinarof cream 1% once daily for plaque psoriasis: A long-term extension trial of a novel therapeutic aryl hydrocarbon receptor modulating agent. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 29-Oct. 2, 2021 (virtual meeting).

Disclosures: Stein Gold reports consulting for Arcutis, Amgen, Bristol Myers Squibb, Dermavant Sciences Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic and UCB Pharma; receiving grants from Arcutis, Amgen, Dermavant Sciences Inc., Eli Lilly, LEO Pharma and Ortho Dermatologic; and receiving payment for the development of educational presentations from Amgen, LEO Pharma and Ortho Dermatologic.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Long-term treatment with tapinarof cream 1% was well tolerated and effective in continuing plaque psoriasis improvement, according to an extension study presented at the EADV Congress virtual meeting.

“The phase 3 PSOARING 3 trial results demonstrated that tapinarof cream was well tolerated long term, with a safety profile consistent with the pivotal studies and previously reported interim analysis of data from PSOARING 3,” Linda Stein Gold, MD, director of dermatology clinical research at the Henry Ford Health System and one of the study’s lead investigators, told Healio in an email correspondence.

Stein Gold presented data from the 40-week PSOARING 3 open-label, multicenter extension trial, which enrolled patients who had completed PSOARING 1 or PSOARING 2 — both double-blind, 12-week trials — and evaluated the safety and efficacy of tapinarof cream in patients during repeated, intermittent treatment.

Linda Stein Gold

Complete disease clearance was achieved in 40.9% of patients at least once during the trial, with 58.2% of patients with a Physician Global Assessment score of 2 or more achieving a PGA of 0 or 1 at least once during the study.

At week 40, 16.9% had PGA of 0 and 44.3% had PGA of 0 or 1. Following treatment, the median duration of remittive effect was 4 months.

“There was a lasting effect to the disease clearance that lasted about 4 months. This has the potential to give some patients the possibility of a periodic drug holiday,” Stein Gold said. “As a clinician I am excited about these final results from PSOARING 3 and the potential for tapinarof to be a new treatment options for patients suffering from plaque psoriasis.”